Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma

Published on :

SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.

Kite to Bolster Cell Therapy Capabilities through Acquisition of Carl June’s Tmunity Therapeutics

Published on :

A Gilead Sciences company, Kite announced Tmunity’s next-generation CAR-T therapies and technology will complement its own cell therapy research capabilities. Kite’s acquisition of Tmunity, founded by Carl June, creates a strong bridge between the BioHealth Capital Region, where Kite maintains its manufacturing capabilities in Frederick, and the Greater Philadelphia biohub.

Arcellx And Kite Announce Strategic Collaboration To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma

Published on :

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.  Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.

“DNA Valley” Continues to Flourish in Maryland, the Birthplace of the Human Genome Project

Published on :

Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.

Announcing Your 3rd Annual BioBuzz Awards Finalists

Published on :

We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

Arcellx Inc. Inks Deal for Expansion Into Newly Converted Lab Space in Rockville

Published on :

The newly minted public company, a clinical-stage provider of cell therapies for cancer and autoimmune diseases, has signed a lease for 60,000 square feet at 800 King Farm Blvd., a roughly 215,000-square-foot office building that Miami-based Banyan Street Capital will convert into office and lab space for life sciences companies. Banyan Street had acquired an ownership stake in 800 King Farm, as well as 700 and 702 King Farm Blvd., in 2020, according to JLL.

Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares

Published on :

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds raised in the offering were $128.8 million, before deducting underwriting discounts and commissions and offering expenses, payable by Arcellx. All shares in the offering were offered by Arcellx.

ASCO: ‘Any way you slice’ it, Arcellx’s CAR-T is matching J&J-Legend’s Carvykti, analyst says

Published on :

Arcellx took a risk by including more patients with a tougher, more aggressive form of multiple myeloma in an early-stage trial for its CAR-T med. But it doesn’t matter, because “any way you slice” it, the small biotech seems to have put up strong enough data to rival the market-leading therapy by Johnson & Johnson and Legend Biotech.
Maryland-based Arcellx presented the latest on CART-ddBCMA, its BCMA-specific CAR-modified T-cell therapy for multiple myeloma, at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Friday.
The data comes from a phase 1 study of patients with relapsed or refractory multiple myeloma, including 31 eligible for an efficacy and safety analysis who had at least three prior lines of treatment. Out of these patients, 21 had “poor prognostic factors,” including extramedullary disease, which means cancer that has spread to form tumors outside the bone marrow in the soft tissues of the body.

Arcellx – Leveling Up By Challenging Assumptions

Published on :

One year after Rami Elghandour joined Arcellx, Inc., a cell therapy company based in Gaithersburg, MD, and Foster City, CA, as the company’s new chairman and CEO, he took the company public, netting $128 million and funding operations into the second half of 2023. If the IPO had occurred in 2020 or 2021, it may not have been all that surprising. Instead, Arcellx completed its IPO in February 2022, a time when key biotech stock indexes continued a precipitous drop that began in the second half of 2021, causing many biopharma companies to delay IPO plans indefinitely.
It wasn’t Elghandour’s first rodeo. In 2011, he led a $58 million Series B financing round for Nevro Corp., a Silicon Valley-based neuromodulation medical device company, representing Johnson & Johnson Development Corporation (JJDC), where he worked as principal, venture investments. In 2012 Elghandour departed JJDC for Nevro, and was promoted to president in 2014, and CEO in 2016. Nevro went public in 2014, completing its IPO with net proceeds of approximately $131 million. The experience of Nevro’s pre-COVID IPO road show, which Elghandour describes as “brutal, but memorable,” was a learning experience. The biggest difference between Nevro’s IPO in 2014 and Arcellx’s IPO…

Rethinking Your Company’s Visual Brand Part 2 – Investing in Better Imagery

Published on :

Last week, we delved into why visual branding is important in helping your life science company stand out from the crowd to attract audiences such as investors and potential talent. We also provided a few tips on how to start thinking about your company’s science and approach differently so that you could create a style that is all your own. With Part 2 of this series, we want to help provide resources and inspiration to up your imagery game.